All In Biotech

Drug Trial Radar · NCT07660198

Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents

A PHASE 3, RANDOMIZED DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A CATCH-UP VACCINATION REGIMEN OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN AND ADOLESCENTS

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

Jun 15, 2026

Primary completion

Dec 2, 2027

Study completion Dec 2, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 15 months, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and otitis media (ear infections) in children when compared to the pneumococcal vaccine that is currently in use, 20vPnC (Prevnar 20®). This study will test if the new pneumococcal vaccine is as safe as the one that is currently in use. It will also assess how the new vaccine works in comparison to the one that is currently in use. To measure how the new pneumococcal vaccine compares to the current one, blood samples will be used to measure the body's ability to create proteins to fight those germs. This new vaccine can possibly provide additional protection against germs that cause pneumococcal disease that are not included in the vaccines that are currently given to children. Pneumococcal disease includes a variety of infections caused by a specific germ, Streptococcus pneumoniae This study is seeking participants who: * Are children aged 15 months to 18 years. * May or may not have received any doses of pneumococcal conjugate vaccine (PCV) in the past. The study will be conducted in the United States, Puerto Rico, and other countries. Participants will be assigned to 1 of 3 groups based on age: Group 1: 15 months to less than 2 years (about 300 participants) Group 2: 2 years to less than 5 years (about 300 participants) Group 3: 5 years to less than 18 years (about 600 participants) Within each group, participants will be assigned by chance in a 2:1 ratio to receive 1 vaccine injection (shot) with either PG4 (new vaccine) or 20vPnC, given in the arm or thigh. This means that for every 3 participants, about 2 will receive PG4 and about 1 will receive 20vPnC. Each participant will take part in the study for approximately 6 months. During this time, each participant will visit a clinic 2 times (visit 1 for vaccination and visit 2 to follow up) and will be contacted via telephone once (for a 6 month follow up). At the study clinic visits, participants will have their blood drawn and be asked if they have experienced any side effects. A side effect is an unintentional or unexpected reaction to a vaccine. During the 6-month follow-up contact, participants will be asked about any further side effects.

Conditions

  • Pneumococcal Disease

Interventions

  • PG4Biological

    Multivalent Pneumococcal Vaccine

  • 20-valent pneumococcal conjugate vaccine (20vPnC)Biological

    20-valent pneumococcal conjugate vaccine (20vPnC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Local Reactions Within 7 Days After VaccinationTime frame: Within 7 days after Vaccination
  2. Percentage of Participants With Systemic Events Within 7 Days after VaccinationTime frame: Within 7 days after Vaccination
  3. Percentage of Participants With Adverse Events (AEs)Time frame: From Vaccination to 1 month after Vaccination
  4. Percentage of Participants With Serious Adverse Events (SAEs)Time frame: From Vaccination to 6 months after Vaccination
  5. GMCs of serotype-specific IgG concentrationsTime frame: 1 month after vaccination
  6. GMTs of serotype-specific OPA titersTime frame: 1 month after vaccination

Locations

77 sites in 4 countries. Site status is shown where the registry gives one.

  • Alabama Clinical Therapeutics, LLC Birmingham Pediatric Associates

    Birmingham, Alabama · Recruiting

  • UAB Child Health Research Unit (CHRU)

    Birmingham, Alabama · Recruiting

  • Lakeview Clinical Research, LLC

    Guntersville, Alabama · Recruiting

  • Apex Research Group

    Fair Oaks, California · Recruiting

  • Orange County Research Institute

    Ontario, California · Recruiting

  • Children's Hospital Colorado

    Aurora, Colorado · Recruiting

  • Riveldi and Associates

    Miami Lakes, Florida · Recruiting

  • Indago Research & Health Center, Inc

    Miami Lakes, Florida · Recruiting

  • South Tampa Center for Advanced Healthcare- USF Health

    Tampa, Florida · Recruiting

  • USF Health

    Tampa, Florida · Recruiting

  • USF Health Department of Pediatrics The Chalsty Clinics at the Curran Children's Health Center (CMS)

    Tampa, Florida · Recruiting

  • Children's Health Center

    Tampa, Florida · Recruiting

  • Medical Research Partners

    Ammon, Idaho · Recruiting

  • Bingham Memorial Hospital

    Blackfoot, Idaho · Recruiting

  • ASR, LLC

    Boise, Idaho · Recruiting

  • Kentucky Pediatric/ Adult Research

    Bardstown, Kentucky · Recruiting

  • Avacare

    Covington, Louisiana · Recruiting

  • Velocity Clinical Research, Lafayette

    Lafayette, Louisiana · Recruiting

  • LSU Health Shreveport Clinical Trials Office

    Shreveport, Louisiana · Recruiting

  • Ochsner/LSU Health Shreveport - Progressive Pediatrics

    Shreveport, Louisiana · Recruiting

  • Ochsner LSU Health Shreveport Ambulatory Care Center

    Shreveport, Louisiana · Recruiting

  • Ochsner/LSU Health Shreveport Academic Medical Center

    Shreveport, Louisiana · Recruiting

  • Pediatric Associates of Fall River

    Fall River, Massachusetts · Recruiting

  • Michigan Center of Medical Research

    Bingham Farms, Michigan · Recruiting

  • Clinical Research Institute, Inc.

    Minneapolis, Minnesota · Recruiting

  • Midwest Children's Health Research Institute

    Lincoln, Nebraska · Recruiting

  • Midwest Children's Health Research Institute

    Lincoln, Nebraska · Recruiting

  • Midwest Children's Health Research Institute

    Lincoln, Nebraska · Recruiting

  • Midwest Children's Health Research Institute

    Lincoln, Nebraska · Recruiting

  • Child Health Care Associates

    East Syracuse, New York · Recruiting

  • Corning Center for Clinical Research

    Horseheads, New York · Recruiting

  • University of Rochester Medical Center

    Rochester, New York · Recruiting

  • Cincinnati Children's Hospital Medical Center Investigational Drug Services

    Cincinnati, Ohio · Recruiting

  • Cincinnati Children's Hospital Medical Center Vaccine Research Center

    Cincinnati, Ohio · Recruiting

  • Pediatric Associates of Mt. Carmel

    Cincinnati, Ohio · Recruiting

  • Dayton Clinical Research

    Dayton, Ohio · Recruiting

  • Senders Pediatrics

    South Euclid, Ohio · Recruiting

  • Tribe Clinical Research LLC. at Parkside Pediatrics Five Forks

    Simpsonville, South Carolina · Recruiting

  • Pediatric Clinical Trials of Tennessee, LLC

    Tullahoma, Tennessee · Recruiting

  • South Texas Clinical Research

    Corpus Christi, Texas · Recruiting

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.